Tier 2 — strong

Role of betaine in improving the antidepressant effect of S-adenosyl-methionine in patients with mild-to-moderate depression

Francesco Di Pierro, Rossana Orsi, Roberto Settembre
Journal of multidisciplinary healthcare 2015 8:39-45

Bibliography

PubMed
PMID 25653537
PubMed Central
PMC4303396
DOI
10.2147/JMDH.S77766
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignRandomized adjunctive pilot
ModelHuman participants
Sample46 adults with inadequately controlled mild-to-moderate depression
InterventionSAMe plus betaine versus SAMe alone alongside existing treatment
Duration90 days
EndpointsDepressive symptoms; Tolerability

What the study showed, in plain terms

Published in 2015, this source examined brain health and combination interventions. Design: Randomized adjunctive pilot. Sample/model: 46 adults with inadequately controlled mild-to-moderate depression. The exposure or intervention was SAMe plus betaine versus SAMe alone alongside existing treatment. Follow-up or treatment period: 90 days.

Both groups improved, with more favorable symptom scores after the SAMe-betaine combination at the final assessment.

Small adjunctive study; product and combination effects cannot be generalized to TMG monotherapy.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Both groups improved, with more favorable symptom scores after the SAMe-betaine combination at the final assessment.
  • The recorded outcome domains were Depressive symptoms; Tolerability.
  • The result applies to the tested exposure: SAMe plus betaine versus SAMe alone alongside existing treatment; 90 days.

What this study can and cannot tell us

  • Small adjunctive study; product and combination effects cannot be generalized to TMG monotherapy.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Betaine: A Promising Natural Product for Neurological and Psychiatric Diseases
Ying Zhang et al. · Current neuropharmacology · 2026
Tier 4
Association of trimethylamine oxide and its precursors with cognitive impairment: a systematic review and meta-analysis
Caiyi Long et al. · Frontiers in aging neuroscience · 2024
Tier 2
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients
D Knopman et al. · Alzheimer disease and associated disorders · 2001
Tier 4
Global DNA hypomethylation and its correlation to the betaine level in peripheral blood of patients with schizophrenia
Yui Murata et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2020
Tier 2
A study of the treatment of Rett syndrome with folate and betaine
Daniel G Glaze et al. · Journal of child neurology · 2009
Tier 2
A placebo-controlled trial of folic acid and betaine in identical twins with Angelman syndrome
Julia Han et al. · Orphanet journal of rare diseases · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology